Category Archives: IP Rights

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

European Commission publishes negotiating proposals for EU-Indonesia trade deal

It is important to note that the EU proposals on IP are TRIPS-plus in multiple regards and would surely reduce policy space in Indonesia and negatively impact access to affordable medicines.  Even a preliminary review of the proposal reveals: A … Continue reading

Posted in IPR Enforcement, Patent Term Extension, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Can drug firms increase health-care access, or just their profits?

Anne Aerts, head of Novartis Foundation, addresses a conference in Basel, Switzerland, looking at the role of drug companies in building health systems. (Credit: Kiara Barnes/Novartis) BASEL, Switzerland — The controversial Swiss pharmaceutical company Novartis has started work to expand … Continue reading

Posted in Drug prices, Novartis Case, Uncategorized | 2 Comments

In pics: Delhi Network of Positive People at Embassies of RCEP negotiating countries

As the next Regional Comprehensive Economic Partnership (RCEP) trade agreement rounds are set to take place in Tianjin, China, from 17-21 October, Delhi Network of Positive People urges all the negotiating countries to reject any terms in the deal that … Continue reading

Posted in Data Exclusivity, FTA, IPR Enforcement, Regional Comprehensive Economic Partnership, TPP, TRIPS plus, Uncategorized | Leave a comment

Open Letter to Ambassadors (in India) of RCEP negotiating countries by Delhi Network of Positive People

Open Letter to Ambassadors of RCEP negotiating countries  Member countries Must Consider the Impact of RCEP on Access to Medicines in Developing Countries  Don’t trade our lives away! We are writing to you on behalf of the Delhi Network of … Continue reading

Posted in Data Exclusivity, FTA, Investor state dispute, IPR Enforcement, LDC transition period, Regional Comprehensive Economic Partnership, TRIPS plus, UN General Assembly HLM | Leave a comment

GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries

Source: GSK Press Release, 31 March 2016 Adopts approach to intellectual property reflecting a country’s economic maturity Will not file for patent protection in Least Developed and Low Income Countries Will seek to grant licences to generic manufacturers to supply … Continue reading

Posted in IP Rights, LDCs, Medicine Patent Pool, Patent, Uncategorized | Leave a comment

Why India needs to show some spine

 Leena Menghaney, The Hindu| April 3, 2016 In the area of intellectual property, public health and access to medicines, the Narendra Modi government should consider its independence to be of the utmost importance. Strong government leadership as well as flexible … Continue reading

Posted in Compulsory Licensing, IP Rights, Uncategorized | Leave a comment